Univariate regression models for overall mortality
Factor (no. of patients dying/all patients) . | Hazard ratio . | 95% Cl . | P . |
|---|---|---|---|
| Conditioning regimen | |||
| Other regimens (11/17) | 1 | — | — |
| Targeted BUCY (9/39) | 0.3 | 0.1-0.8 | .01 |
| Platelet count | |||
| × 109/L or higher (10/40) | 1 | — | — |
| Less than × 109/L (9/15) | 3.6 | 1.4-8.9 | .006 |
| Dupriez classification | |||
| 1 (4/25) | 1 | — | — |
| 2 (7/17) | 2.9 | 0.9-10.1 | .09 |
| 3 (8/13) | 6.5 | 2.0-22.0 | .002 |
| Degree of fibrosis | |||
| 1 (4/21) | 1 | — | — |
| 2 (7/17) | 2.9 | 0.8-9.9 | .09 |
| 3 (9/18) | 3.7 | 1.1-12.1 | .03 |
| Karyotype | |||
| Normal (6/29) | 1 | — | — |
| Clonal (11/21) | 5 | 1.5-18.2 | .009 |
| Age, y | |||
| Modeled as a continuous linear variable | Increasing age, increasing hazard | — | .07 |
| Age, y | |||
| Younger than 40 (5/19) | 1 | — | — |
| 40 to 50 (7/20) | 1.3 | 0.4-4.2 | .61 |
| Older than 50 (8/17) | 2.5 | 0.8-7.6 | .12 |
| Splenectomy | |||
| No (14/36) | 1 | — | — |
| Yes (6/20) | 0.8 | 0.3-2.0 | .58 |
| Excess blasts | |||
| No (17/51) | 1 | — | — |
| Yes (3/5) | 1.8 | 0.5-6.2 | .34 |
| Source of stem cells | |||
| BM (13/33) | 1 | — | — |
| PBSC (7/23) | 1.1 | 0.4-2.8 | .88 |
| Donor | |||
| Unrelated or mismatched related (10/25) | 1 | — | — |
| HLA-identical sibling (10/31) | 0.7 | 0.3-1.7 | .42 |
| Disease duration, modeled as a continuous linear variable | — | — | .85 |
Factor (no. of patients dying/all patients) . | Hazard ratio . | 95% Cl . | P . |
|---|---|---|---|
| Conditioning regimen | |||
| Other regimens (11/17) | 1 | — | — |
| Targeted BUCY (9/39) | 0.3 | 0.1-0.8 | .01 |
| Platelet count | |||
| × 109/L or higher (10/40) | 1 | — | — |
| Less than × 109/L (9/15) | 3.6 | 1.4-8.9 | .006 |
| Dupriez classification | |||
| 1 (4/25) | 1 | — | — |
| 2 (7/17) | 2.9 | 0.9-10.1 | .09 |
| 3 (8/13) | 6.5 | 2.0-22.0 | .002 |
| Degree of fibrosis | |||
| 1 (4/21) | 1 | — | — |
| 2 (7/17) | 2.9 | 0.8-9.9 | .09 |
| 3 (9/18) | 3.7 | 1.1-12.1 | .03 |
| Karyotype | |||
| Normal (6/29) | 1 | — | — |
| Clonal (11/21) | 5 | 1.5-18.2 | .009 |
| Age, y | |||
| Modeled as a continuous linear variable | Increasing age, increasing hazard | — | .07 |
| Age, y | |||
| Younger than 40 (5/19) | 1 | — | — |
| 40 to 50 (7/20) | 1.3 | 0.4-4.2 | .61 |
| Older than 50 (8/17) | 2.5 | 0.8-7.6 | .12 |
| Splenectomy | |||
| No (14/36) | 1 | — | — |
| Yes (6/20) | 0.8 | 0.3-2.0 | .58 |
| Excess blasts | |||
| No (17/51) | 1 | — | — |
| Yes (3/5) | 1.8 | 0.5-6.2 | .34 |
| Source of stem cells | |||
| BM (13/33) | 1 | — | — |
| PBSC (7/23) | 1.1 | 0.4-2.8 | .88 |
| Donor | |||
| Unrelated or mismatched related (10/25) | 1 | — | — |
| HLA-identical sibling (10/31) | 0.7 | 0.3-1.7 | .42 |
| Disease duration, modeled as a continuous linear variable | — | — | .85 |
BM indicates bone marrow; PBSC, peripheral blood stem cell.